| Dr Mohammed Islam, MD | |
|
Rbmc 530 New Brunswick Ave, Dept Of Internal Medicine, Perth Amboy, NJ 08861 | |
| (732) 324-5080 | |
| (732) 324-4669 |
| Full Name | Dr Mohammed Islam |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 36 Years |
| Location | Rbmc 530 New Brunswick Ave, Perth Amboy, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114938461 | NPI | - | NPPES |
| 129026 | Medicaid | AZ | |
| 01004682204 | Other | NJ | AMERICHOICE (MIDDLESEX) |
| P00800130 | Other | NJ | RR MEDICARE |
| 0170241 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 35847 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Raritan Bay Medical Center Perth Amboy Division | Perth amboy, NJ | Hospital |
| Riverview Medical Center | Red bank, NJ | Hospital |
| Jfk Medical Center | Edison, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Two River Physician Associates | 0648594820 | 12 |
| Central Jersey Medical Center Inc. | 1456301241 | 24 |
| Hackensack Meridian Health Medical Group - Primary Care Pc | 7911003330 | 273 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
| Entity Name | Central Jersey Medical Center Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932974250 PECOS PAC ID: 1456301241 Enrollment ID: O20050712000392 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Complex Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154379626 PECOS PAC ID: 0446272298 Enrollment ID: O20060109000000 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Primary Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336203538 PECOS PAC ID: 7911003330 Enrollment ID: O20070502000000 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
| Entity Name | Two River Physician Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417354333 PECOS PAC ID: 0648594820 Enrollment ID: O20150116000462 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
| Entity Name | Hospitalist Physicians Of New Jersey Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588021851 PECOS PAC ID: 3476859927 Enrollment ID: O20160309000541 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
| Entity Name | Liberty Med Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366983033 PECOS PAC ID: 7416234075 Enrollment ID: O20170509000044 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohammed Islam, MD 1808 Plaza Dr, Woodbridge, NJ 07095-1127 Ph: (732) 675-1035 | Dr Mohammed Islam, MD Rbmc 530 New Brunswick Ave, Dept Of Internal Medicine, Perth Amboy, NJ 08861 Ph: (732) 324-5080 |
News Archive
The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.
The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.
New data suggest that the drug Topamax and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
› Verified 7 days ago
Pankaj R Shirolawala, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 609 Amboy Ave Ste 101, Perth Amboy, NJ 08861 Phone: 732-442-2211 Fax: 732-326-0517 | |
Dr. Mahesh H Bhagat, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 530 New Brunswick Ave, Perth Amboy, NJ 08861 Phone: 732-442-3700 | |
Poonam Pamini Jani, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 Hobart St, Perth Amboy, NJ 08861 Phone: 732-376-9333 Fax: 732-293-0139 | |
Dr. Alissa Kay Holman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 530 New Brunswick Ave, Perth Amboy, NJ 08861 Phone: 732-442-3700 | |
Sana Ahsun, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 275 Hobart St, Perth Amboy, NJ 08861 Phone: 732-376-9333 | |
Cynthia Vuittonet, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 275 Hobart St, Perth Amboy, NJ 08861 Phone: 732-376-9333 |